{"id":1192,"date":"2008-04-01T12:06:00","date_gmt":"2008-04-01T10:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/kontroversen-um-das-negative-ergebnis-der-cholesterinsenker-studie-enhance"},"modified":"2008-04-01T12:06:00","modified_gmt":"2008-04-01T10:06:00","slug":"kontroversen-um-das-negative-ergebnis-der-cholesterinsenker-studie-enhance","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/kontroversen-um-das-negative-ergebnis-der-cholesterinsenker-studie-enhance","title":{"rendered":"Kontroversen um das negative Ergebnis der Cholesterinsenker-Studie ENHANCE"},"content":{"rendered":"<p>Das Kombinationspr\u00e4parat Ezetimib\/Simvastatin 10 mg\/80 mg (Inegy\u00ae, USA: Vytorin\u00ae; Merck\/Schering-Plough) gilt nach Verkaufszahlen (2007: w\u00f6chentlich 1 Mio. Verschreibungen weltweit, 5 Milliarden US$ Jahresumsatz) bereits als \u201eBlockbuster-Drug\u201d. Durch den zu Statinen komplement\u00e4ren Wirkmechanismus von Ezetimib (Reduktion der enteralen Cholesterin-Resorption) kann eine zus\u00e4tzliche LDL-Cholesterin-Reduktion von ca. 20% erreicht werden (1). Daten zu klinischen Endpunkten liegen trotz der [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Das Kombinationspr\u00e4parat Ezetimib\/Simvastatin 10 mg\/80 mg (Inegy\u00ae, USA: Vytorin\u00ae; Merck\/Schering-Plough) gilt nach Verkaufszahlen (2007: w\u00f6chentlich 1 Mio. Verschreibungen weltweit, 5 Milliarden US$ Jahresumsatz) bereits als \u201eBlockbuster-Drug\u201d. Durch den zu Statinen komplement\u00e4ren Wirkmechanismus von Ezetimib (Reduktion der enteralen Cholesterin-Resorption) kann eine zus\u00e4tzliche LDL-Cholesterin-Reduktion von ca. 20% erreicht werden (1). Daten zu klinischen Endpunkten liegen trotz der [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2878,451,449,2914,2879,455,453,456,505,443],"class_list":["post-1192","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-cholesterin-resorptionshemmer","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-enhance-studie","tag-ezetimib","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-lipidsenker","tag-simvastatin","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1192"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1192\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}